Drug intelligence / Profile preview

CHXM-002

Development stage: Preclinical
Lead developer: ChomiX Biotech
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

CHXM-002 is an experimental radionuclide drug conjugate (RDC) currently in the hit identification stage of preclinical development by ChomiX. The drug is designed using ChomiX's proprietary chemoproteomics platform, which identifies novel ligands for previously undruggable targets. CHXM-002 consists of a small molecule targeting a specific membrane protein expressed on tumor cells, conjugated to a radionuclide payload. This approach is intended to deliver localized, lethal radiation directly to cancerous tissues while sparing healthy cells. It is being developed as a targeted therapy for various solid tumors.

Beyond the preview

Go deeper on CHXM-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHXM-002.

Explore the full profile